| Literature DB >> 35893824 |
Yanina P Hecker1, Mercedes M Burucúa1, Franco Fiorani1,2, Jaime E Maldonado Rivera2,3, Karina M Cirone1,2, Matías A Dorsch2,4, Felipe A Cheuquepán1, Lucía M Campero1, Germán J Cantón1, Maia S Marín1, Luis M Ortega-Mora5, Dadín P Moore1,2.
Abstract
Neospora caninum is recognised for causing cattle abortion, provoking severe economic losses in the livestock industry worldwide. The aim of the present study was to evaluate the reactivation and foetal infection in pregnant heifers inoculated with live N. caninum tachyzoites before puberty. A total of 15 30-month-old pregnant heifers were allocated into four groups: animals inoculated with live tachyzoites of NC-Argentina LP1 isolate before puberty and challenged with live tachyzoites of NC-1 strain at 210 days of gestation (DG) (Group A); animals mock inoculated before puberty and challenged with NC-1 strain at 210 DG (Group B), animals inoculated before puberty but not subsequently challenged (Group C); and noninfected and nonchallenged animals (Group D). The results of this study showed that 100% of animals infected before puberty (Groups A and C) suffered reactivation of the infection at the seventh month of gestation. In addition, in three and two calves from Groups A and C, respectively, congenital infection was confirmed. Interestingly, we provide evidence that the use of live N. caninum tachyzoites in young animals as a strategy to induce protection is neither safe nor effective.Entities:
Keywords: Neospora caninum; bovine; efficacy; live parasite; prepubertal inoculation; reactivation; safety; vertical transmission
Year: 2022 PMID: 35893824 PMCID: PMC9330614 DOI: 10.3390/vaccines10081175
Source DB: PubMed Journal: Vaccines (Basel) ISSN: 2076-393X
Figure 1Chronological layout of the experiment. A chronological summary of Experiments 1 and 2 is depicted. Experiment 1 involved the inoculation of prepubertal female calves with the Neospora NC-Argentina LP1 isolate (already described in [11]), while Experiment 2 involved the results included in the present study.
Study design and groups. (1) BP: before reaching puberty; (2) DG: days of gestation.
| Group ( | Treatment BP (1) | Challenged at 210 DG (2) with NC-1 | Evaluation of |
|---|---|---|---|
| A (4) | 1 × 106 live tachyzoites of NC-Argentina LP1 strain | Yes | Protection |
| B (4) | PBS | Yes | Challenge control |
| C (4) | 1 × 106 live tachyzoites of NC-Argentina LP1 strain | No | Reactivation |
| D (3) | PBS | No | Negative control |
Figure 2Longitudinal profile of immunoglobulin G (IgG) and subisotypes in heifers from different experimental groups assessed by iELISA. Each dot represents the mean ± standard deviation (SD) at different sampling times. (a) Mean ± SD of the relative index percentages (RIPC) ± SD of total IgG throughout gestation in Groups A (inoculated and challenged (I-C)), B (placebo and challenged (P-C)), C (inoculated and not challenged (I-nC)), and D (placebo and not challenged (P-nC)). Cut-off: ≥8.2 RIPC. *** p < 0.0001. ** p < 0.001. The upwards arrow marks the day of challenge (210 days of gestation). (b) Mean Neospora-specific IgG1/IgG2 ratio ± SD of animals in Groups A and C at 6, 7, 8, and 9 months of gestation. Lowercase letters indicate significant differences within the same group over time. The upwards arrow marks the day of challenge (210 days of gestation).
Reactivation study in inoculated heifers in the last 4 months of gestation. I-C: inoculated and challenged; P-C: placebo and challenged; I-nC: inoculated not challenged; P-nC: placebo not challenged. PBMCs: peripheral blood mononuclear cells. IB: immunoblot. 1 Cut-off 1:100; 2 Cut-off 1:25; 3 Cut-off 1:100; 4 From PBMC. + and − indicate a positive and negative result, respectively, for each of the assays. Lowercase letters (a and b) indicate significant differences between different groups.
| Groups | Months of Gestation | 6 | 7 | 8 | 9 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Heifers | ELISA 1 | IFAT 2 | IB 3 | PCR 4 | ELISA 1 | IFAT 2 | IB 3 | PCR 4 | ELISA 1 | IFAT 2 | IB 3 | PCR 4 | ELISA 1 | IFAT 2 | IB 3 | PCR 4 | |
| A | #4 | − | 25 a | + | − | + | 100 a | + | + | + | 12,800 a | + | − | + | 6400 b | + | + |
| (I-C) | #5 | − | 100 a | + | − | + | 800 a | + | + | + | 25,600 a | + | − | + | 6400 b | + | + |
| #9 | − | 25 a | − | − | − | 100 a | − | + | + | 25,600 a | + | + | + | 12,800 b | + | − | |
| #12 | − | 100 a | + | + | + | 1600 a | + | + | + | 12,800 a | + | + | + | 800 b | + | + | |
| B | #32 | − | − b | − | − | − | − b | − | − | + | 12,800 a | + | − | + | 51,200 a | + | − |
| (P-C) | #34 | − | − b | − | − | − | − b | − | − | + | 12,800 a | + | − | + | 25,600 a | + | − |
| #38 | − | − b | − | − | − | − b | − | − | + | 25,600 a | + | − | + | 6400 a | + | − | |
| #47 | − | − b | − | − | − | − b | − | − | + | 25,600 a | + | − | + | 6400 a | + | − | |
| C | #2 | − | 100 a | + | − | + | 400 a | + | + | + | 800 b | + | + | + | 1600 b | − | − |
| (I-nC) | #14 | − | 25 a | − | − | + | 400 a | + | + | + | 200 b | + | − | + | 200 b | + | − |
| #18 | − | 25 a | + | − | − | 100 a | + | + | + | 3200 b | + | − | + | 3200 b | − | − | |
| #19 | − | 50 a | + | − | + | 400 a | + | + | + | 800 b | + | + | + | 3200 b | + | − | |
| D | #30 | − | − b | − | − | − | − b | − | − | − | − c | − | − | − | − c | − | − |
| (P-nC) | #47a | − | − b | − | − | − | − b | − | − | − | − c | − | − | − | − c | − | − |
| #48 | − | − b | − | − | − | − b | − | − | − | − c | − | − | − | − c | − | − | |
N. caninum-serological status in dams and their offspring from different groups at delivery, before colostrum intake. I-C: inoculated and challenged; P-C: placebo and challenged; I-nC: inoculated not challenged; P-nC: placebo not challenged. PBMC: peripheral blood mononuclear cells. 1 Antibody detection by either iELISA, IFAT, or IB; 2 Cut-off 1:100; 3 Cut-off 1:25. + and − indicate a positive and negative result, respectively, for each of the assays.
| Experimental Groups | Dams | Calves | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ID | Specific IgG 1 | ID | Specific IgG 1 | |||||||
| Serum 2 | Colostrum 1 | Placenta | PBMC | Colostrum | Serum 3 | Umbilical Cord | PBMC | |||
| A (I-C) | #4 | + | + | − | + | − | #1 | + | − | − |
| #5 | + | + | + | + | − | #6 | + | + | − | |
| #9 | + | + | − | − | − | #9 | + | − | − | |
| #12 | + | − | − | + | − | Aborted foetus | − | − | − | |
| B (P-C) | #32 | + | + | − | − | − | #3 | + | − | − |
| #34 | + | − | − | − | − | #4 | + | − | − | |
| #38 | + | − | − | − | − | #14 | + | − | − | |
| #47 | + | − | − | − | − | #13 | + | − | − | |
| C (I-nC) | #2 | + | − | − | − | − | #11 | − | − | − |
| #14 | + | − | − | − | − | #12 | + | − | − | |
| #18 | + | + | − | − | − | #5 | + | − | − | |
| #19 | + | + | − | − | − | #10 | − | − | − | |
| D (P-nC) | #30 | − | − | − | − | − | #8 | − | − | − |
| #47a | − | − | − | − | − | #15 | − | − | − | |
| #48 | − | − | − | − | − | #2 | − | − | − | |
Figure 3Interleaved-bar graphs of relative cytokine mRNA expression levels in PBMCs in heifers from Groups A (inoculated and challenged (I-C)), B (placebo and challenged (P-C)), and C (inoculated and not challenged (I-nC)). Relative quantification of cytokine mRNA expression levels was carried out using the 2−ΔΔCt method. The numbers on the Y-axis represent the mean fold change in cytokine mRNA expression levels relative to Group D (placebo and no challenge (P-nC), i.e., the negative control). Error bars represent the SD. (a) IL-10; (b) INF-γ; (c) TNF-α; (d) IL-12 p40; and (e) IL-4. Upwards arrow: day of challenge (210 days of gestation). The significant differences among groups were analysed. *** p < 0.0001; ** p < 0.001; * p < 0.05. Letters indicate significant differences in each group over time.